PHARMACOGENETICS AND GLAUCOMA THERAPEUTICS

药物遗传学和青光眼治疗

• 批准号: 7376549
• 负责人: Sayoko E Moroi
• 金额: $ 4.75万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-05 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376549
• 关键词: eye; genetics; glaucoma

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It is well known that individuals show variable responses to drug treatments. For example, in patients taking drugs to treat glaucoma, some individuals have a good response with eye pressure lowering to a drug, while others show only a marginal response, and yet still others suffer adverse effects from the same drug. Such variable responses to drugs among patients are caused by a combination of biological mechanisms, environmental factors, and the genetic make up of the individual patient. The science behind pharmacogenetics is based on understanding the relationship between gene variations, called polymorphisms, and individual variations in drug response. These genetic polymorphisms may be potential markers for predicting drug response in an individual patient. The goal of Dr. Moroi's project is to determine whether genetic variations in the glaucoma drug target genes and related pathways account for the observed variation in eye pressure response to glaucoma drugs used to lower eye pressure in the treatment of glaucoma. In this study, Dr. Moroi will study the individual response to the glaucoma medications using a noninvasive procedure called fluorophotometry. This instrument can measure the eye's change in fluid production in response to glaucoma medications.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。众所周知，个体对药物治疗的反应各不相同。例如，在服用药物治疗青光眼的患者中，一些人对药物的眼压降低有良好的反应，而另一些人仅表现出边际反应，还有一些人对同一药物产生不良反应。患者对药物的这种不同反应是由生物机制、环境因素和个体患者的遗传组成综合作用引起的。药物遗传学背后的科学基于理解基因变异（称为多态性）与药物反应的个体差异之间的关系。这些遗传多态性可能是预测个体患者药物反应的潜在标记。 Moroi 博士项目的目标是确定青光眼药物靶基因和相关途径的遗传变异是否可以解释所观察到的青光眼治疗中用于降低眼压的青光眼药物的眼压反应变化。在这项研究中，森井博士将使用一种称为荧光光度法的非侵入性方法来研究个体对青光眼药物的反应。该仪器可以测量眼睛因青光眼药物而产生的液体产生的变化。